Melanoma-specific bcl-2 promotes a protumoral M2-like phenotype by tumor-associated macrophages.
Animals
Apoptosis
Cell Differentiation
Cell Movement
Cell Proliferation
Female
Humans
Melanoma
/ immunology
Mice
Mice, Inbred C57BL
Monocytes
/ immunology
Phenotype
Proto-Oncogene Proteins c-bcl-2
/ metabolism
Tumor Cells, Cultured
Tumor Microenvironment
/ immunology
Tumor-Associated Macrophages
/ immunology
Xenograft Model Antitumor Assays
macrophages
melanoma
tumor microenvironment
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
accepted:
14
03
2020
entrez:
10
4
2020
pubmed:
10
4
2020
medline:
19
3
2021
Statut:
ppublish
Résumé
A bidirectional crosstalk between tumor cells and the surrounding microenvironment contributes to tumor progression and response to therapy. Our previous studies have demonstrated that bcl-2 affects melanoma progression and regulates the tumor microenvironment. The aim of this study was to evaluate whether bcl-2 expression in melanoma cells could influence tumor-promoting functions of tumor-associated macrophages, a major constituent of the tumor microenvironment that affects anticancer immunity favoring tumor progression. THP-1 monocytic cells, monocyte-derived macrophages and melanoma cells expressing different levels of bcl-2 protein were used. ELISA, qRT-PCR and Western blot analyses were used to evaluate macrophage polarization markers and protein expression levels. Chromatin immunoprecipitation assay was performed to evaluate transcription factor recruitment at specific promoters. Boyden chamber was used for migration experiments. Cytofluorimetric and immunohistochemical analyses were carried out to evaluate infiltrating macrophages and T cells in melanoma specimens from patients or mice. Higher production of tumor-promoting and chemotactic factors, and M2-polarized activation was observed when macrophages were exposed to culture media from melanoma cells overexpressing bcl-2, while bcl-2 silencing in melanoma cells inhibited the M2 macrophage polarization. In agreement, the number of melanoma-infiltrating macrophages in vivo was increased, in parallel with a greater expression of bcl-2 in tumor cells. Tumor-derived interleukin-1β has been identified as the effector cytokine of bcl-2-dependent macrophage reprogramming, according to reduced tumor growth, decreased number of M2-polarized tumor-associated macrophages and increased number of infiltrating CD4 Taken together, our results show that melanoma-specific bcl-2 controls an IL-1β-driven axis of macrophage diversion that establishes tumor microenvironmental conditions favoring melanoma development. Interfering with this pathway might provide novel therapeutic strategies.
Sections du résumé
BACKGROUND
A bidirectional crosstalk between tumor cells and the surrounding microenvironment contributes to tumor progression and response to therapy. Our previous studies have demonstrated that bcl-2 affects melanoma progression and regulates the tumor microenvironment. The aim of this study was to evaluate whether bcl-2 expression in melanoma cells could influence tumor-promoting functions of tumor-associated macrophages, a major constituent of the tumor microenvironment that affects anticancer immunity favoring tumor progression.
METHODS
THP-1 monocytic cells, monocyte-derived macrophages and melanoma cells expressing different levels of bcl-2 protein were used. ELISA, qRT-PCR and Western blot analyses were used to evaluate macrophage polarization markers and protein expression levels. Chromatin immunoprecipitation assay was performed to evaluate transcription factor recruitment at specific promoters. Boyden chamber was used for migration experiments. Cytofluorimetric and immunohistochemical analyses were carried out to evaluate infiltrating macrophages and T cells in melanoma specimens from patients or mice.
RESULTS
Higher production of tumor-promoting and chemotactic factors, and M2-polarized activation was observed when macrophages were exposed to culture media from melanoma cells overexpressing bcl-2, while bcl-2 silencing in melanoma cells inhibited the M2 macrophage polarization. In agreement, the number of melanoma-infiltrating macrophages in vivo was increased, in parallel with a greater expression of bcl-2 in tumor cells. Tumor-derived interleukin-1β has been identified as the effector cytokine of bcl-2-dependent macrophage reprogramming, according to reduced tumor growth, decreased number of M2-polarized tumor-associated macrophages and increased number of infiltrating CD4
CONCLUSIONS
Taken together, our results show that melanoma-specific bcl-2 controls an IL-1β-driven axis of macrophage diversion that establishes tumor microenvironmental conditions favoring melanoma development. Interfering with this pathway might provide novel therapeutic strategies.
Identifiants
pubmed: 32269145
pii: jitc-2019-000489
doi: 10.1136/jitc-2019-000489
pmc: PMC7254128
pii:
doi:
Substances chimiques
BCL2 protein, human
0
Proto-Oncogene Proteins c-bcl-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
FASEB J. 2002 Sep;16(11):1453-5
pubmed: 12205045
Nat Commun. 2018 Jul 27;9(1):2951
pubmed: 30054470
Int J Cancer. 2014 Aug 15;135(4):843-61
pubmed: 24458546
J Immunol. 2007 Aug 15;179(4):2330-8
pubmed: 17675494
Nature. 2011 Jun 08;475(7355):222-5
pubmed: 21654748
Blood. 2011 Nov 17;118(20):5498-505
pubmed: 21972293
Int J Cancer. 2000 Apr 15;86(2):188-96
pubmed: 10738245
Cell. 2010 Apr 2;141(1):39-51
pubmed: 20371344
Adv Cancer Res. 2015;128:95-139
pubmed: 26216631
Cancer Metastasis Rev. 2006 Sep;25(3):387-408
pubmed: 17043764
J Control Release. 2016 Feb 10;223:165-177
pubmed: 26742942
Mol Cancer Res. 2011 Nov;9(11):1537-50
pubmed: 21954434
Cancer Res. 2016 Jun 1;76(11):3145-55
pubmed: 27013197
Carcinogenesis. 2009 Mar;30(3):377-86
pubmed: 19136477
J Biol Chem. 1990 Dec 5;265(34):21128-33
pubmed: 2250017
Melanoma Res. 2014 Jun;24(3):237-43
pubmed: 24667300
Br J Cancer. 2016 Jul 12;115(2):145-55
pubmed: 27336610
J Biol Chem. 2004 Feb 20;279(8):6737-45
pubmed: 14660675
Dev Cell. 2017 Dec 4;43(5):549-562.e6
pubmed: 29207258
Carcinogenesis. 2013 Nov;34(11):2558-67
pubmed: 23836782
Oncol Lett. 2018 Apr;15(4):5399-5404
pubmed: 29552183
Immunol Rev. 2018 Jan;281(1):8-27
pubmed: 29247995
Nat Rev Cancer. 2016 Mar;16(3):173-86
pubmed: 26868177
J Cell Physiol. 2005 Dec;205(3):414-21
pubmed: 15920759
Nat Cell Biol. 2017 Oct;19(10):1226-1236
pubmed: 28945232
J Biol Chem. 2014 May 23;289(21):15118-29
pubmed: 24711453
Int J Exp Pathol. 2006 Jun;87(3):163-76
pubmed: 16709225
Semin Cancer Biol. 2008 Oct;18(5):349-55
pubmed: 18467122
Immunol Invest. 2012;41(6-7):635-57
pubmed: 23017139
Nat Rev Immunol. 2009 Aug;9(8):556-67
pubmed: 19575028
Cancer Res. 2013 Feb 1;73(3):1128-41
pubmed: 23221383
Int J Oncol. 2006 Mar;28(3):661-6
pubmed: 16465371
Mol Carcinog. 2016 Dec;55(12):2304-2312
pubmed: 26599548
PLoS One. 2015 Aug 12;10(8):e0134320
pubmed: 26267609
J Invest Dermatol. 2015 Sep;135(9):2155-2161
pubmed: 25947358
J Immunol. 2005 Jul 1;175(1):461-8
pubmed: 15972680
J Immunol. 1994 Sep 1;153(5):2052-63
pubmed: 8051410
Proc Natl Acad Sci U S A. 2019 Jan 22;116(4):1361-1369
pubmed: 30545915
Immunol Rev. 2018 Jan;281(1):57-61
pubmed: 29247996
J Exp Clin Cancer Res. 2018 Nov 19;37(1):278
pubmed: 30454024
PLoS One. 2014 Jun 12;9(6):e99568
pubmed: 24924428
World J Surg Oncol. 2008 Jun 20;6:65
pubmed: 18570663
Mol Oncol. 2007 Dec;1(3):288-302
pubmed: 18509509
Cell Death Differ. 2011 Jun;18(6):1024-35
pubmed: 21233846
J Exp Med. 2008 Jun 9;205(6):1261-8
pubmed: 18490490
Biochem J. 1994 Sep 15;302 ( Pt 3):723-7
pubmed: 7945196
Cell. 2015 Sep 10;162(6):1257-70
pubmed: 26343581
J Immunol. 2003 Dec 15;171(12):6448-56
pubmed: 14662844
Nat Rev Immunol. 2012 Mar 22;12(4):253-68
pubmed: 22437938
Leuk Lymphoma. 2013 Aug;54(8):1823-5
pubmed: 23614795
Cell Death Dis. 2016 Feb 11;7:e2090
pubmed: 26866271